Complications of therapy with intravenous cidofovir

Severe nephrotoxicity and anterior uveitis

Daniel J. Skiest, Mai Duong, Susanna Park, Lisa Wei, Philip Keiser

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Intravenous cidofovir is a new drug approved for the treatment of cytomegalovirus retinitis. Mild to moderate renal impairment was reported in 12%-17% of patients in two recent clinical trials. Uveitis was not reported as a complication in these trials. The first 20 patients treated with cidofovir at a large urban county hospital HIV clinic were reviewed. Three patients developed severe nephrotoxicity, two of whom died. In addition, five cases of anterior uveitis (two of whom also had renal failure), which occurred after receiving a mean of 5.4 (range, 2-13) cidofovir doses, were noted. One patient developed a cataract related to prior cidofovir-induced uveitis. Risk factors for nephrotoxicity seemed to include a prior episode of renal impairment, concomitant or prior nephrotoxic agents, and inconsistent dosing, which was due to patients not taking all of the prescribed doses of probenecid. Risk factors for uveitis seemed to include prior or concurrent renal impairment (three of five patients) and concomitant use of protease inhibitors (five of five patients). Uveitis improved with topical corticosteroids; however, recurrence of symptoms was noted in the two patients in whom cidofovir was continued. Intravenous cidofovir should be administered cautiously, after careful patient screening, to avoid potentially serious toxicities.

Original languageEnglish (US)
Pages (from-to)151-157
Number of pages7
JournalInfectious Diseases in Clinical Practice
Volume8
Issue number3
StatePublished - 1999
Externally publishedYes

Fingerprint

Anterior Uveitis
Uveitis
Therapeutics
Kidney
Cytomegalovirus Retinitis
cidofovir
County Hospitals
Probenecid
Urban Hospitals
Protease Inhibitors
Cataract
Renal Insufficiency
Adrenal Cortex Hormones
Clinical Trials
HIV
Recurrence

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Complications of therapy with intravenous cidofovir : Severe nephrotoxicity and anterior uveitis. / Skiest, Daniel J.; Duong, Mai; Park, Susanna; Wei, Lisa; Keiser, Philip.

In: Infectious Diseases in Clinical Practice, Vol. 8, No. 3, 1999, p. 151-157.

Research output: Contribution to journalArticle

Skiest, Daniel J. ; Duong, Mai ; Park, Susanna ; Wei, Lisa ; Keiser, Philip. / Complications of therapy with intravenous cidofovir : Severe nephrotoxicity and anterior uveitis. In: Infectious Diseases in Clinical Practice. 1999 ; Vol. 8, No. 3. pp. 151-157.
@article{b985c869eace451186f77d4e6c30e759,
title = "Complications of therapy with intravenous cidofovir: Severe nephrotoxicity and anterior uveitis",
abstract = "Intravenous cidofovir is a new drug approved for the treatment of cytomegalovirus retinitis. Mild to moderate renal impairment was reported in 12{\%}-17{\%} of patients in two recent clinical trials. Uveitis was not reported as a complication in these trials. The first 20 patients treated with cidofovir at a large urban county hospital HIV clinic were reviewed. Three patients developed severe nephrotoxicity, two of whom died. In addition, five cases of anterior uveitis (two of whom also had renal failure), which occurred after receiving a mean of 5.4 (range, 2-13) cidofovir doses, were noted. One patient developed a cataract related to prior cidofovir-induced uveitis. Risk factors for nephrotoxicity seemed to include a prior episode of renal impairment, concomitant or prior nephrotoxic agents, and inconsistent dosing, which was due to patients not taking all of the prescribed doses of probenecid. Risk factors for uveitis seemed to include prior or concurrent renal impairment (three of five patients) and concomitant use of protease inhibitors (five of five patients). Uveitis improved with topical corticosteroids; however, recurrence of symptoms was noted in the two patients in whom cidofovir was continued. Intravenous cidofovir should be administered cautiously, after careful patient screening, to avoid potentially serious toxicities.",
author = "Skiest, {Daniel J.} and Mai Duong and Susanna Park and Lisa Wei and Philip Keiser",
year = "1999",
language = "English (US)",
volume = "8",
pages = "151--157",
journal = "Infectious Diseases in Clinical Practice",
issn = "1056-9103",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Complications of therapy with intravenous cidofovir

T2 - Severe nephrotoxicity and anterior uveitis

AU - Skiest, Daniel J.

AU - Duong, Mai

AU - Park, Susanna

AU - Wei, Lisa

AU - Keiser, Philip

PY - 1999

Y1 - 1999

N2 - Intravenous cidofovir is a new drug approved for the treatment of cytomegalovirus retinitis. Mild to moderate renal impairment was reported in 12%-17% of patients in two recent clinical trials. Uveitis was not reported as a complication in these trials. The first 20 patients treated with cidofovir at a large urban county hospital HIV clinic were reviewed. Three patients developed severe nephrotoxicity, two of whom died. In addition, five cases of anterior uveitis (two of whom also had renal failure), which occurred after receiving a mean of 5.4 (range, 2-13) cidofovir doses, were noted. One patient developed a cataract related to prior cidofovir-induced uveitis. Risk factors for nephrotoxicity seemed to include a prior episode of renal impairment, concomitant or prior nephrotoxic agents, and inconsistent dosing, which was due to patients not taking all of the prescribed doses of probenecid. Risk factors for uveitis seemed to include prior or concurrent renal impairment (three of five patients) and concomitant use of protease inhibitors (five of five patients). Uveitis improved with topical corticosteroids; however, recurrence of symptoms was noted in the two patients in whom cidofovir was continued. Intravenous cidofovir should be administered cautiously, after careful patient screening, to avoid potentially serious toxicities.

AB - Intravenous cidofovir is a new drug approved for the treatment of cytomegalovirus retinitis. Mild to moderate renal impairment was reported in 12%-17% of patients in two recent clinical trials. Uveitis was not reported as a complication in these trials. The first 20 patients treated with cidofovir at a large urban county hospital HIV clinic were reviewed. Three patients developed severe nephrotoxicity, two of whom died. In addition, five cases of anterior uveitis (two of whom also had renal failure), which occurred after receiving a mean of 5.4 (range, 2-13) cidofovir doses, were noted. One patient developed a cataract related to prior cidofovir-induced uveitis. Risk factors for nephrotoxicity seemed to include a prior episode of renal impairment, concomitant or prior nephrotoxic agents, and inconsistent dosing, which was due to patients not taking all of the prescribed doses of probenecid. Risk factors for uveitis seemed to include prior or concurrent renal impairment (three of five patients) and concomitant use of protease inhibitors (five of five patients). Uveitis improved with topical corticosteroids; however, recurrence of symptoms was noted in the two patients in whom cidofovir was continued. Intravenous cidofovir should be administered cautiously, after careful patient screening, to avoid potentially serious toxicities.

UR - http://www.scopus.com/inward/record.url?scp=0032941457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032941457&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 151

EP - 157

JO - Infectious Diseases in Clinical Practice

JF - Infectious Diseases in Clinical Practice

SN - 1056-9103

IS - 3

ER -